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GRAND ROUNDS PANEL DISCUSSION

Blood Thinners Peri-Operatively: What to do?
Jad AL Danaf, MD, MPH (Facilitator), Anusha Govind, MD, Loheetha Ragupathi, MD, and Shuwei Wang, MD

PANELISTS
Mathew DeCaro, MD: Associate Professor of
Cardiology, Director of the Coronary Cardiac Unit,
Cardiology fellowship program director
John Doherty, MD: Professor of Cardiology
Gregary Markefka, MD: Associate Professor of
Cardiology, Associate Director of the Coronary
Cardiac Unit, Cardiology fellowship assistant
program director
Geno Merli, MD: Professor of Vascular Medicine,
Co-director of Jefferson Vascular Center
Srikanth Nagalla, MD, MS: Associate Professor of
Medicine, Director, Clinical Hematology

Before starting the case discussions, here are some
definitions with respect to AC and AP agents:
• Interrupt: Omit one or more doses of the agent,
based on the bleeding risk
• Bridge: Substitute the oral agent with a parenteral
agent, based on the thrombotic risk
• Elective surgery: Can/should be delayed until the
patient is medically stable.
• Urgent surgery: Needs to be done within 48 hours,
needs quick attention and can be delayed for
medical stability. This includes oncologic surgeries
• Emergent surgery: Needs to be done immediately,
otherwise the patient will die.

Eric Schwenk, MD: Assistant Professor of
Anesthesiology, Director of orthopedic anesthesia

The general approach to the perioperative management
of blood thinners depends on 4 major steps4:

Barry Ziring, MD: Clinical Associate Professor of
Internal Medicine / Primary Care, Director of the
division of Internal Medicine

1. Estimating thromboembolic or ischemic risk

INTRODUCTION
The population size today is increasing and becoming
more of an aging population. This carries with it a package
of chronic illnesses associated with aging and particularly
the need for surgeries.
Atrial fibrillation is the most common arrhythmia causing
approximately 20% of ischemic stroke cases with
estimated annual costs of $6 billion in the United States1,2.
Many patients undergoing surgeries are on blood thinning
agents; either oral antiplatelet (AP) for established
coronary artery disease of anticoagulants (AC) for atrial
fibrillation or thromboembolic disease, putting them at
risk of bleeding. It is estimated that about 5-15% of patients
undergoing coronary stent implantation are expected to
undergo a surgical procedure within 2 years3.
Hence, it is of utmost importance to be familiar with the
perioperative management of AP and AC agents to
balance the risks of thromboembolic events, ischemic
cardiac events and bleeding. The key to such management
is extensive benefit-risk discussions with patients and
seamless coordination within a multidisciplinary team of
surgeons, interventional proceduralists, anesthesiologists,
hematologists, vascular medicine specialists, cardiologists,
primary care physicians and nurses. We present a case
based multidisciplinary panel discussion to facilitate better
understanding of this topic.
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2. Estimating the bleeding risk (surgical, anesthesia type
and patient factors)
3. Deciding whether and when to interrupt the AC or
AP agents
4. Deciding whether there is a need for bridging
therapy until the oral agent can be resumed

PERIOPERATIVE MANAGEMENT
OF AC AGENTS
A modified risk stratification by Douketis et al of the
consensus statement on the perioperative management
of antithrombotic therapy is presented in Table 1 as
published in 20124. Estimating the thromboembolic risk
depends on three main illness categories: presence of a
mechanical heart valve, atrial fibrillation and venous
thromboembolic disease. Patients at very high risk of
thromboembolic phenomena should either be continued
on their AC agents perioperatively or bridged with a
parenteral agent. Patients with low to moderate risk of
thromboembolic phenomena can be safely managed
perioperatively off their AC agents in case of high risk of
bleeding that necessitates cessation of the AC agent.
The thrombotic risk drives the decision for bridging and the
bleeding risk drives the decision for AC interruption. A
risk-benefit ratio will dictate the most suitable plan of action
in every patient, and in most scenarios, these decisions
differ from case to case.
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Table 1: Estimates of Thromboembolic Risks
Risk Category

Very high

Mechanical valve

AF

VTE

• MV prosthesis

• CHA2DS2-VASc 6-9

• VTE: 3 months

• Cage-ball or tilting disc AV

• Stroke/TIA: 3 months

• Stroke/TIA: 6 months

• Rheumatic valve

• Severe thrombophilia
(protein C or S deficiency,
AT III deficiency, APLS)
• VTE: 3-12 months

High

Bileaflet AV +: AF, stroke/TIA,
HTN, DM, CHF, >75 years old

CHA2DS2-VASc 4-5

• Thrombophilia: FV-Leiden,
prothrombin gene mutation
• Recurrent VTE
• Active Cancer

Low-moderate

Bileaflet AV + No other risk factors

CHA2DS2-VASc 2-3,
no TIA/Stroke

VTE >12 months

AF: atrial fibrillation; VTE: venous thromboembolism; MV: mitral valve; AV: aortic valve; TIA: transient ischemic attack; HTN: hypertension; DM: diabetes mellitus;
CHF: congestive heart failure; AT: antithormbin; APLS: anti phospholipid syndrome; FV: factor five. Modified from Douketis JD et al.4

Table 2: Estimates of Bleeding Risk
Risk category

Type of Surgery

Patient factors

• High risk* (cardiac, vascular, general surgery, kidney biopsy, polypectomy, bilateral knee,
laminectomy, neurosurgery, urological)
• Low risk** (eye, cholecystectomy, hysterectomy, tooth extraction, endoscopy+biopsy,
pacemaker, bronchoscopy + biopsies, knee, hip, arthroscopy)
• HAS-BLED score (hypertension, abnormal renal or liver function (two points for both), stroke,
bleeding tendency, labile INRs, elderly age, and antiplatelet drugs or alcohol). Total 9 points.
• High risk: >3 points (HR 11.8, 95% CI 5.6-24.9) according to the BORDER registry

HR: Hazard ratio; *A high risk of bleeding is defined as a 2-4% risk of a major bleed within 2 days post-operatively; **A low risk of bleeding is defined as a 0-2%
risk of a major bleed within 2 days post-operatively; Data from Spyropoulos et al6.

Table 3: Bridging Therapy Management Peri-Operatively.
Bleeding risk

Pre-operative

Post-operative

• Start on day-3 when stopped Warfarin day -5
Low

• Omit dose on day 0
• Omit evening dose day -1 if BID dose

Resume therapeutic dose day 1, if
hemostasis is secure

• 50% total dose if OD day-1
• Start on day-3 when stopped Warfarin day -5
High

• Omit dose on day 0
• Omit evening dose day -1 if BID dose
• 50% total dose OD day -1

Resume therapeutic dose days 2-3 if
hemostasis is secure
OR
Low dose LMWH (30 or 40mg) when
hemostasis is secure

BID: twice a day; OD: once a day; TIA: transient ischemic attack; Data from Douketis et al4, Douketis et al7, Hirsh et al8.
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The bleeding risk is estimated based on surgical risk and
patient’s risk. A major bleed is generally defined as bleeding
that is fatal, intracranial, requires surgery to correct, lowers
the hemoglobin by ≥2 g/dL, or requires transfusion of ≥2
units of packed red blood cells5.
The goal of bridging is to minimize the patient’s time being
off the oral anticoagulant for more protection against
thromboembolic events. The commonly used agents are
subcutaneous enoxaparin or parenteral unfractionated
heparin which have similar safety profiles and efficacy.
However, the risk of bleeding should be also factored in
while deciding when to start and stop the bridging agent.
The available consensus statements on bridging
management are summarized in table3 4,7,8.
To note, most of the above recommendations are either
class 2b or 2c recommendations, and cannot be considered
guidelines as per the definition of guidelines; rather they
reflect consensus statements based on the published
available body of evidence.

heparin (LMWH) on the same day after surgery, so they might
recommend either lower doses or prophylactic doses.
Dr. Doherty: There was a survey that was recently sent out
to the ACC members and asked :” Does your institution
have a well structured process on how to manage perioperatively?”; and only one percent said they had a
comprehensive well structured system on how to manage
these patients perioperatively.
Audience: Can the panel comment on the appropriate
time to stop heparin prior to surgery? We have had internal
differences in opinions and recommendations.
Dr. Nagalla: The ACCP guidelines recommend stopping
heparin 4-6 hours prior to surgery. For LMWH, the
recommendation is at least 24 hours4. There are also some
situations when we may need to use 40mg of enoxaparin
instead of a therapeutic dose 24 hours prior to surgery in
cases of high risk of bleeding in need for bridging therapy.
Suggested management plan for case 1:

The following are transcription of case discussions among
the different experts regarding their recommendations for
perioperative management of each patient.

• Stop warfarin day-5

Case 1: Warfarin

• Resume warfarin within 24 hours after surgery
(usual dose).

A 76-year-old female with non-valvular atrial fibrillation,
hypertension, and prior stroke six months ago, receiving
warfarin, requires elective hip replacement with neuraxial
anesthesia; renal function is normal, and weight is 75 kg.
CHA2DS2-VASc=6 → Very high risk of thrombosis and high
risk of bleeding
Dr. DeCaro: I tend to treat patients with a previous stroke
aggressively irrespective of the time frame, so I would
bridge this patient perioperatively.
Dr. Shwenck: We leave the decision to the orthopedic
surgeons to determine the urgency of the procedure and if
it can be delayed. We will still follow the currently available
guidelines particularly concerning bridging.
Dr. DeCaro: We would also stop heparin at midnight prior
to the procedure.
Dr.Merli: There is a study in Annals of Internal Medicine9
that showed no anti-Xa effect on the morning of the surgery
if the enoxaparin is stopped 24 hours prior to surgery.
Audience: When we try to risk assess, we multiply the
likelihood by the impact of an illness. For example, if 100
people had something done and 98% will do well, that’s a
great likelihood ration. The impact of having something go
bad, such as paralysis can affect the remaining 2%.
Therefore, when we individualize care, patients should
understand the risks that they are agreeing to and quoting
likelihood of success is less meaningful that weighing both
the likelihood of success and impact of failure.
Dr. Merli: I don’t think any orthopedic surgeon would allow
their patients to receive a full dose of low molecular weight

Published by Jefferson Digital Commons, 2016

• Preoperative bridging with LMWH day-3, with last
dose on the morning of day-1.

• Postoperative low dose LMWH for VTE prevention
within 24 hours after surgery until postoperative
bridging is started.
• Postoperative bridging on postoperative day 2 or 3,
when hemostasis is secured; continue for at least
4-5 days, until the INR is therapeutic.

Case 2: Rivaroxaban
A 68-year-old female with non-valvular atrial fibrillation,
hypertension, and congestive heart failure, receiving
rivaroxaban 15 mg daily in the morning, requires a dental
cleaning and two dental extractions; CrCl is 35 mL/min.
CHA2DS2-VASc score = 4 → high risk of thrombosis and
low risk of bleeding
Dr. Merli: I would not bridge this patient and would stop
rivaroxaban. She is on the lower dose, so the question is
when to stop it. ASRA guidelines 10 are not for dental
procedures. Within 48 hours (4 half lives), rivaroxaban
should be cleared, and 3 days for Xa inhibitors. I would
restart rivaroxaban 24 hours after the procedure, and would
think of an alternative drug for the future due to her low
CrCl, such as warfarin.
Dr. Nagalla: I would treat her differently; I would not stop
rivaroxaban and would use local pro-hemostatic agents
such as tranexamic acid mouthwash. Hold dose on day of
procedure, restart with next dose.
Dr. Ziring: In the community they are less tolerant of
bleeding so we tend to stop the oral AC sooner.
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Dr. Doherty: This would be a proceed-uninterrupted plan if
a patient is taking Warfarin. The answer of this case might
be different in 5 years due to the expanding data of direct
acting anticoagulants (DOACS). Shall we delay the morning
dose or omit the dose on that day?
Suggested management plan for case 2:
• Stop rivaroxaban on the day of the procedure.
• Use oral tranexamic acid mouthwash just before the
procedure and two to three times that day after the
procedure.
• Resume rivaroxaban the day after the procedure,
after at least 24 hours have elapsed (assuming the
dental extractions were uneventful).

Case 3: Apixaban
A 55 year old male with an unprovoked deep vein thrombosis
(DVT) four months ago, receiving apixaban 5 mg twice
daily, who requires a colonoscopy because of a personal
history of premalignant colorectal polyps with planned
polypectomy; renal function is normal.
→ high risk of thrombosis and high risk of bleeding
Dr. Nagalla: It was noticed that the highest risk of thrombosis
recurrence is within 3 months of the VTE. In this case, since
the DVT is >3 months ago, we would focus more on the
bleeding risk as compared to the thrombotic risk; Stopping
Apixaban 48 hours prior to the procedure is reasonable,
with no bridging, and resuming Apixaban after 24hours. We
can also give them 2.5mg of Apixaban 12 hours after the
procedure then resume full dose 24hours after the
procedure.
Dr. Merli: I agree with Dr. Nagalla, I would stop it 48 hours
prior to the procedure. The guidelines from ASRA are for
regional anesthesia, so we have to be careful in interpreting
these results.

Case 4: Warfarin
A 69-year-old male with chronic atrial fibrillation and
hypertension on Warfarin, requires a Whipple surgery for
pancreatic adenocarcinoma.
CHA2DS2-VASc score = 2 → low-moderate risk of
thrombosis and high risk of bleeding
Dr. Ziring: Moderate risk is based on CHA2DS2-VASc risk
but this patient has other risks of thrombosis: cancer and
undergoing a major surgery. Therefore here are two
approaches:
• Not bridge and restart coumadin + Sub-cutaneous
heparin DVT prophylaxis
• LMWH before surgery, discontinue it prior to surgery,
after surgery restart LMWH at lower dose, increase to
full dose at time of discharge. Removes this
confusion of pills and bridging.
Dr.Doherty: If the patient is ambulatory, the thrombotic risk
is acceptably low. Risk is not stroke or systemic embolism;
rather it is mainly of DVT. Therefore, post-op needs
prophylactic dose prior to full dose enoxaparin or warfarin.
Dr. DeCaro: So post-op, transitioning to Warfarin, I would
give DVT prophylaxis until INR is therapeutic on Warfarin.
Dr. Nagalla: There is an advantage of Warfarin post-op.
Bowel resection; the advantage of using warfarin is that we
have an INR to monitor as compared to DOACs. Patients
on DOACs were excluded from most studies.
Suggested management plan for case 4:
• Stop Warfarin day-5
• No bridging
• Resume Warfarin day of surgery.
• Use sub-cutaneous heparin or LMWH for DVT
prophylaxis on day of surgery onwards until INR is
therapeutic

Audience: How would the answer change if the case is of
a PE instead of a DVT?

Case 5: Rivaroxaban and regional anesthesia

Dr. Nagalla: Depends on the severity of a PE: Hemodynamic
stability and if within the past 3 months, need for
thrombolysis...etc. So even for PE, same risk stratification
should take place.

A 65 yo male with history of AF and hypertension taking
rivaroxaban presents for primary total hip replacement. He
denies any history of diabetes, coronary artery disease,
stroke, or heart failure. Hemoglobin 14.0.

Dr. Doherty: This case can be divided to what you do pre
and postop, because with a normal renal function, you can
hold one dose of Apixaban, emphasizing that you almost
never bridge patients on DOACs. If it ends up being a large
polyp, or a tiny polyp or no polyp, then post procedurally
management differs.

CHA2DS2-VASc score = 2 → low-moderate risk of
thrombosis and low risk of bleeding

Suggested management plan for case 3:
• Stop apixaban day-2
• No bridging
• Resume apixaban days 2-3 after the polypectomy/
colonoscopy.
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Dr. Schwenk: This is a common case. First thing, what is
the bleeding risk? Primary hip replacement is important to
distinguish from revision or more complicated hip surgeries.
Thus the bleeding risk falls into the intermediate bleeding
risk category. Second thing, what is the surgeon’s and
anesthesiologist’s preference? We have an institutional
practice that the surgeons prefer regional anesthesia, but I
believe that the benefits of neuraxial anesthesia is
exaggerated since most of the data is based on retrospective
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data analysis. Third question is whether we need to bridge
or not? And with what agent?
ASRA are working on the 4th edition11 of anticoagulation
management perioperatively and they published a draft
table highlighting the recommended time intervals before
and after neuraxial block or epidural catheter removal.
Dr. Merli: I would stop rivaroxaban for 2 days and restart it
in the orthopedic dose of 10mg post procedurally, whenever
the surgeons are ok with us restarting it. If anesthesiologists
prefer 3 days, I would be ok with it as well. When do we go
to the regular dose? Cardiologists may say in 2 weeks
post-op? But we don’t know what the correct answer is.
Some surgeons might even object to using rivaroxaban
post-op. Should we use Warfarin instead? Or LMWH? These
are nebulous questions. I would not bridge upfront and
would restart rivoraxaban post-op.
Suggested management plan for case 5:
• Stop Rivaroxaban day-3 to reduce risk of spinal
hematoma (may need longer with impaired CrCl or
other agents that increase bleeding risk)
• No Bridging
• Resume Rivaroxaban day +1, if team prefers to delay,
consider LMWH or SQH for DVT prophylaxis

Perioperative management of AP agents
The general approach to managing patients on antiplatelet
agents preoperatively is similar to that for Anticoagulant
agents. Defining the fine balance between ischemic and
bleeding risk remains a challenge in patients with coronary
stents undergoing surgery treated with antiplatelet therapy.
The risk of recurrent ischemic events for patients
discontinuing or not adhering to aspirin treatment has been
suggested to increase 3-fold12. Stent thrombosis is a serious
complication that commonly presents with death or a
significant nonfatal myocardial infarction. Ischemic events
are more common after the premature discontinuation of
a second antiplatelet agent such as clopidogrel and it can
be explained by “withdrawal of protection”12. This can be
accomplished by avoiding drug-eluting stents whenever
possible, especially in patients with known poor adherence
to medical therapy and with any anticipated surgeries.
Figure 1 highlights a suggested algorithm for perioperative
management of patients on AP agents, as presented by Di
Minno et al in 201313.
Low risk situations are defined as > 14 days post balloon
angioplasty, > 6 weeks post bare metal stent and > 6
months post drug eluting stent. If the patients is at low risk
of major adverse cardiac events and have a low risk of
bleeding, then the dual AP agents can be discontinued, but
it is preferred if Aspirin is continued.

Figure 1. Algorithm for perioperative management of antiplatelet therapy.
Adapted from Di Minno et al.13
ADP: adenosine diphosphate; ASA: aspirin; PTCA: percutaneous transluminal coronary
angioplasty; BMS: bare metal stent; DES: drug-eluting stent; MI: myocardial infarction;
ST: stent thrombosis.
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Case 6: Dual AP agents post DES

CONCLUSION

68-year-old man with a sirolimus-eluting coronary stent
inserted 4 months ago following NSTEMI. Now requires
surgery for removal of a parotid neoplasm (adenocarcinoma → Urgent surgery

Managing patients on blood thinners perioperatively can be
very challenging and an optimal approach is an interdisciplinary discussion weighing the benefits to risks of stopping
the agent or bridging whenever necessary. Patients should
be fully informed of the risks of thrombosis versus bleeding
when consenting to the plan. The available consensus
statements have been serving as “guidelines”, but as our
expert panelists have reminded us, they are class 2
recommendations formed by expert consensus. It is
important to take these recommendations in the context of
every patient for an individualized approach to treatment.

ASA, 81 mg + clopidogrel, 75 mg daily
CABG 8 years ago, Hypertension, Type 2 diabetes
→ high risk of thrombosis and low risk of bleeding
Dr. Marhefka: In patients who had an MI, the observational
data shows that up to a year there are complications with
non-cardiac surgeries. We don’t use sirolimus stents
anymore, which are considered first generation stents. But
if we had a patient with that such as in our case, and is
beyond a year, we would be comfortable stopping the
second AP agents but not the aspirin (ASA). Therefore, with
a first generation stent, we would continue the surgery on
ASA. We would push for surgery on double AP agents if it is
4 months post stenting, or delay the surgery to at least 1
year and then do the surgery only on ASA. If the case is of
a second-generation stent, there is data with xerolimus and
everolimus that showed evidence of 3 months of dual AP
therapy is enough, but keep in mind that an NSTEMI was
recent.
Dr. DeCaro: Our surgeons have reached a certain comfort
level performing surgeries on dual AP agents.
Dr. Nagalla: One option might be to stop the AP agent,
bridge with heparin and then restart the agent post-op.
Audience: This area needs more evidence to know how to
manage AP agents. We have to respect the surgeon’s
preferences, even if it is anecdotal or cultural rather than
evidence based since they are the ones performing the
surgery.
Suggested management plan for case 6:
• Optimal to delay surgery to at least 6 months
after DES
• Since it is urgent due to active malignancy, and
low risk of bleed, will proceed with surgery on
DAPT without interruption.
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